NEW YORK (GenomeWeb) – Consulting firm Diaceutics announced today that it has signed an agreement to obtain real-time patient testing data from BioReference Laboratories, which it will use to help pharmaceutical industry clients accelerate the rollouts of new cancer drugs.
Under the terms of the five-year deal, Diaceutics will have access to BioReference diagnostic data from 50,000 patient samples per day, which it will combine with existing datasets it has accumulated through partnerships with other labs. The firm will use the aggregated data to help its customers better understand the testing patterns of physicians considering precision medicine therapies for patients.
Additional terms were not disclosed.
"Diagnostic data from laboratories like BioReference help pharmaceutical companies better understand the testing journey that patients go on in the often difficult search for a targeted therapy determined by biomarkers," Diaceutics CEO Peter Keeling said in a statement. "That information allows pharma to pinpoint patients that need to be on a specific ... drug, accelerate speed to market for new drugs, and improve patient outcomes."